Efficacy of interferon treatment for chronic hepatitis C predicted by feature subset selection and support vector machine

Journal of Medical Systems

Volumn 31, Issue 2, 2007, Pages 117-123

  Yang, Jun ^a   Nugroho, Anto Satriyo ^b   Yamauchi, Kazunobu ^a   Yoshioka, Kentaro ^c   Zheng, Jiang ^a   Wang, Kai ^a   Kato, Ken ^a   Kuroyanagi, Susumu ^d   Iwata, Akira ^d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUKYO UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Chronic Hepatitis C (CHC); Feature Subset Selection (FSS); Interferon (IFN); Predict; Support Vector Machine (SVM)

Indexed keywords

ALKALINE PHOSPHATASE; CHOLINESTERASE; INTERFERON; VIRUS RNA; ANTIVIRUS AGENT; RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; SUPPORT VECTOR MACHINE; BIOPSY; BLOOD; DECISION SUPPORT SYSTEM; LIVER FUNCTION TEST; MIDDLE AGED; ORGANIZATION AND MANAGEMENT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RNA;

EID: 34249846492     PISSN: 01485598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10916-006-9046-8     Document Type: Article

References (28)

1. Hoofnagle, J. H., Mullen, K. D., Jones, D. B., and Rustgi, V., Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315:1575-1578, 1986.
2. Davis, G. L., Balart, L. A., Schiff, E. R., and Lindsay, K., Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 321:1501-1506, 1989.
3. Di Bisceglie, A. M., Martin, P., Kassianides, C., and Lisker-Melman, M., Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321:1506-1510, 1989.
4. Hagiwara, H., Hayashi, N., Mita, E., and Ueda, K., Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology. 15:37-41, 1992.
5. Lai, M. Y., Kao, J. H., Yang, P. M., Wang, J. T., Chen, P. J., Chan, K. W, Chu, J. S., and Chen, D. S., Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1307-1312, 1996.
6. Reichard, O., Norkrans, G., Fryden, A., Braconier, J. H., Sonnerborg, A., and Weiland O. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:83-87, 1998.
7. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M, Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. H., and Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:958-965, 2001.
8. Fried, M. W., Schiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Hãussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982, 2002.
9. Duda, R. O., Hart, P. E & Stork, D. G. Pattern Classification (2nd ed.). Wiley Interscience. New York, NY, 2000.
10. Cristianini, N., and Shawe-Taylor, J. An Introduction to Support Vector Machines (and other kernel-based learning methods). Cambridge University Press. 2000.
11. EASL Intemational Consensus Conference on hepatitis C. Paris, 26-28, February 1999 Consensus statement. Journal of Hepatology. 30(5): 956-961, 1999.
12. Kiyosawa, K., Sodeyama, T., Tanaka, E., and Gibo, Y. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:671-675, 1990.
13. Tong, M. J., el-Farra, N. S., Reikes, A. R., and Co, R. L. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1463-1466, 1995.
14. Kanai, K., Kako, M., Aikawa, T., and Kumada, T. Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype. Liver. 15:185-188, 1995.
15. Kiyosawa, K. The value of hepatitis C virus genotyping to epidemiological and clinical studies. J. Gastroenterol. Hepatol. 12:623-624, 1997.
16. Chayama, K., Tsubota, A., Kobayashi, M., and Okamoto, K. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 25:745-749, 1997.
17. Kanai, K., Kako, M., and Okamoto, H., HCV genotypes in chronic hepatitis C and response to interferon. Lancet. 339:1543, 1992.
18. Yoshioka, K., Kakumu, S., Wakita, T., and Ishikawa, T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology. 16:293-299, 1992.
19. Nousbaum, J. B., Pol, S., Naloas, B., and Landais, P. Hepatitis C virus type 1b(II) infection in France and Italy. Ann. Intern. Med. 122:161-168, 1995.
20. Davis, G. L., and Lau, J. Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 26(suppl):122S-127S, 1997.
21. Kuo, G., Choo, Q. L., Alter, H. J., and Gitnick, G. L., An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:362-364, 1989
22. Shiratori, S., Kato, N., Yokosuka, O., and Imazeki, F., Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. 113:558-566, 1997.
23. Poynard, T., Bedossa, P., Chevallier, M., and Mathurin, P., A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N. Engl. J. Med. 332:1457-1462, 1995.
24. Lau, J. Y., Davis, G. L., Kniffen, J., and Qian, K. P., Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1501-1504, 1993.
25. Bishop, C., M., Neural Networks for Pattern Recognition, Oxford University Press, 1995.
26. Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., and Ishii, H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J. Clin Microbiol. 43(1):186-191, 2005.
27. Hwang, Y., Chen, E. Y., Gu, Z. J., Chuang, W. L., Yu, M. L., Lai, M. Y., Chao, Y. C., Lee, C. M., Wang, J. H., Dai, C. Y., Shian-Jy Bey, M., Liao, Y. T., Chen, P. J., and Chen, D. S. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics. 7(5):697-709, 2006.
28. Kim, S, R., Hayashi, Y., Yoon, S., Taniguchi, M., Yang, M. K., Kim, K. I., Kim, M. M., Saeki, K., Nukata, I., and Imoto, S. Prediction of efficacy of interferon treatment of chronic hepatitis C by multivariate analysis and a new classification. Pathol Int. 48(3):215-220, 1998.